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Abstract
The evolution of drug-resistance in pathogens is a major global health threat. Elucidating the molecular basis of pathogen
drug-resistance has been the focus of many studies but rarely is it known whether a drug-resistance mechanism identified is
universal for the studied pathogen; it has seldom been clarified whether drug-resistance mechanisms vary with the
pathogen’s genotype. Nevertheless this is of critical importance in gaining an understanding of the complexity of this global
threat and in underpinning epidemiological surveillance of pathogen drug resistance in the field. This study aimed to assess
the molecular and phenotypic heterogeneity that emerges in natural parasite populations under drug treatment pressure.
We studied lines of the protozoan parasite Leishmania (L.) donovani with differential susceptibility to antimonial drugs; the
lines being derived from clinical isolates belonging to two distinct genetic populations that circulate in the leishmaniasis
endemic region of Nepal. Parasite pathways known to be affected by antimonial drugs were characterised on five
experimental levels in the lines of the two populations. Characterisation of DNA sequence, gene expression, protein
expression and thiol levels revealed a number of molecular features that mark antimonial-resistant parasites in only one of
the two populations studied. A final series of in vitro stress phenotyping experiments confirmed this heterogeneity amongst
drug-resistant parasites from the two populations. These data provide evidence that the molecular changes associated with
antimonial-resistance in natural Leishmania populations depend on the genetic background of the Leishmania population,
which has resulted in a divergent set of resistance markers in the Leishmania populations. This heterogeneity of parasite
adaptations provides severe challenges for the control of drug resistance in the field and the design of molecular
surveillance tools for widespread applicability.
Citation: Decuypere S, Vanaerschot M, Brunker K, Imamura H, Mu¨ller S, et al. (2012) Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations
Vary with Genetic Background. PLoS Negl Trop Dis 6(2): e1514. doi:10.1371/journal.pntd.0001514
Editor: Timothy G. Geary, McGill University, Canada
Received August 16, 2011; Accepted December 19, 2011; Published February 28, 2012
Copyright:  2012 Decuypere et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work received financial support from the European Commission (INCO-Dev project LeishNatDrug-R contract FP5-ICA4-CT-2001-10076, Marie Curie
IEF contract FP6 - DonNA-R – 041465, and INCO-Dev project Kaladrug-R contract FP7-222895) and the Baillet–Latour Foundation. This work was also supported by
the Wellcome Trust (WT061173MA-SM). The Wellcome Trust Centre for Molecular Parasitology is supported by core funding from the Wellcome Trust (085349).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jcdujardin@itg.be
Introduction
Leishmania, a protozoan parasite transmitted by phlebotomine
sand flies, causes a neglected infectious disease commonly referred
to as leishmaniasis. The species Leishmania (Leishmania) donovani is
the causative agent of visceral leishmaniasis (VL) or kala-azar, the
most severe form of leishmaniasis which is lethal if left untreated
[1,2]. Pentavalent antimonials, such as sodium stibogluconate
(SSG), have been the first-line treatment for leishmaniasis
worldwide for more than 70 years. However, this therapy is
challenged by emergence of resistant parasites [3–6], a phenom-
enon best documented in the Indian subcontinent with SSG-
resistant L. (L.) donovani being reported in both India [7] and Nepal
[8]. In the late 1990s it was reported that parasite resistance to
antimonials consistently correlated with SSG treatment failure in
the Indian province Bihar [7,9], and appeared to cause up to 60%
treatment failure in that region [5]. In contrast, in the
neighbouring Nepalese VL endemic region VL patients infected
with SSG-resistant parasites were found to have only a 25% risk of
SSG treatment failure [8].
Pentavalent antimonials are considered to have a dual action
mode whereby (i) the administered formulation sodium stiboglu-
conate stimulates the infected macrophages (mW) to impose
oxidative/nitrosative stress on the intracellular parasites [10,11],
and (ii) the reduced form of the drug, trivalent antimony (SbIII),
acts directly on the parasite by perturbing its redox-balance [12–
14]. Figure 1 shows a schematic overview of the cellular processes
known to be affected or involved in the mode of action of
antimonials. The adaptations that Leishmania requires to resist this
complex drug pressure are poorly understood. It has been shown
that SSG-resistant L. (L.) donovani clinical isolates have a polyclonal
origin, which could be explained by frequently and independent
events of SSG-resistance emergence throughout the endemic
region [15–17]. It is not known how variable or invariable the
associated molecular changes are at each emergence event
although results from studies investigating antimonial resistance
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in different L. (L.) donovani clinical isolates have suggested a very
heterogeneous situation. Many different approaches have been
used to study various clinical isolates and this has led to the
tentative identification of multiple putative markers of SSG-
resistance including heat shock proteins [18], histones [19], surface
proteins [20–22], and various transporters [20,21,23–25]. The up-
regulation of antioxidant pathways in SSG-resistant parasites has
been most frequently reported and is thought to entail possible
cross-resistance to oxidative/nitrosative stress [21,23,26–29]. It is
currently not known whether any of these putative markers is
universal to all SSG-resistant parasites and the number of clinical
isolates included in individual studies so far has been too limited to
make conclusions on the homogeneous or heterogeneous charac-
ter of the SSG-resistant parasite population on the Indian
subcontinent [21,23,26–28].
The aim of this study was to address whether or not SSG-
resistant Leishmania emerging in a particular endemic region
evolved via similar molecular adaptations. For this purpose, we
designed a comprehensive characterisation of the parasite
pathways implicated in SSG/SbV/SbIII metabolism using a
collection of parasite strains isolated from Nepalese VL patients.
The resulting data suggest that the SSG-resistant Leishmania
parasites in this single endemic region have heterogeneous
molecular and phenotypic features related to drug resistance.
Our findings highlight the necessity of molecular typing of
emerging drug resistant parasite populations in order to fully
understand the nature, complexity and consequences of the
appearance of drug resistance.
Methods
Ethics statement
Written informed consent was obtained from the patients and in
case of children from the parents or guardians. Ethical clearance
was obtained from the institutional review boards of the Nepal
Health Research Council, Kathmandu, Nepal and the Institute of
Tropical Medicine, Antwerp, Belgium.
Parasites
Parasites were isolated from bone marrow aspirates from
confirmed VL patients recruited at the B.P. Koirala Institute of
Health Sciences, Dharan, Nepal between 2002 and 2003 as
described before [8] with a success rate of approximatively 60%.
All clinical isolates were obtained at time of diagnosis, before SSG
treatment, except for 3 isolates (BPK164/1, BPK177/0 and
BPK181/12) which were obtained at time of adjudged treatment
failure. The methods used for species typing, genotyping and in
vitro antimonial testing of the clinical isolates were performed as
described previously [8]. Briefly, all isolates were typed as L. (L.)
donovani based on a CPB PCR-RFLP assay [30] and were further
genotyped using kDNA PCR-RFLP [15], Illumina whole genome
sequencing [16] and typing of 130 SNPs on the Sequenom
platform [17]. Genotyping of the parasite strain collection used in
this study revealed 2 major genetic clusters, designated here as
population A and B. Population A is very homogenous and
geographically clustered, while population B is heterogeneous
compared to population A and geographically scattered [15].
Selected parasite isolates were cloned using the micro-drop
method [31], to obtain homogenous working parasite populations
for study, which we further refer to as clones. All clones were
confirmed to be L. donovani by CPB PCR-RFLP analysis. All strains
were infectious for macrophages in vitro [8] and 12 of them were
previously studied for infectivity in vivo, showing that all are
infective to BALB/c mice [32]. The in vitro susceptibility of a strain
for SSG or SbIII is expressed as an activity index (A.I.), which is
defined as the ratio of the ED50 of a tested strain versus the ED50
of the SSG-sensitive reference strain included in each assay.
Isolates with an A.I. of 1–2 were considered sensitive to the tested
drug, while isolates with an A.I. of 3 or higher were considered
resistant. The details of all isolates and derived clones included in
this study are given in Table 1.
In vitro promastigote growth
Promastigotes were grown on modified Eagle’s medium [33]
(Invitrogen) supplemented with 20% (v/v) heat inactivated foetal
calf serum (PAA laboratories GmbH) pH 7.5 at 26uC. The
cultures were initiated by inoculating parasites at day 4 stationary
phase into 50 mL culture medium to give a density of 56105
parasites/mL; the resulting inoculated medium was equally
distributed over 10 culture flasks. Every 24 hrs for 8 consecutive
days, parasite density was determined to record parasite growth.
Monitoring of parasite growth and concomitant sampling at
various time-points was repeated for production of DNA extracts
for sequencing, mRNA extracts for gene expression profiling,
protein extracts for protein profiling, metabolite extracts for thiol
profiling and in vitro oxidative and nitrosative stress testing.
DNA sequencing
Promastigote pellets were harvested during stationary phase of
promastigote growth and washed 3 times in PBS. Three flasks of
5 mL cultures were needed for the required yield of 7–10 mg
DNA. DNA isolation was performed from the dry pellets with the
QIAamp DNA Mini Kit, according to manufacturer’s instruc-
tions. From whole-genome sequencing data [16], the sequences of
the 11 target genes and 500 bp upstream/downstream were
retrieved and aligned to check for sequence polymorphism; read-
depth analysis and SNP calling were done as described elsewhere
[16] and the 11 targets all proved to be single-copy per haploid
genome.
RNA isolation, real-time quantitative PCR and
comparative analysis
A promastigote pellet of each studied strain was harvested every
24 hrs for 8 consecutive days of in vitro promastigote growth. RNA
was isolated, analysed and reverse transcribed as described before
Author Summary
Drug resistance is a serious problem that strikes at the core
of infectious disease control. The mechanisms developed
by pathogens to become resistant against existing drug
treatments have been studied for many years but these
studies have frequently scrutinized a few lines of the
pathogen and rarely is it known whether the mechanisms
identified occur in all pathogen populations present in
endemic regions. In this study we assessed the diversity
amongst drug-resistant parasites which emerged under
treatment pressure in a natural parasite population. An
extensive molecular and phenotypic characterisation of a
collection of Leishmania donovani parasites isolated from
leishmaniasis patients revealed that the parasites which
are resistant to treatment have heterogeneous characters.
The results provide evidence that how a parasite develops
resistance under treatment pressure depends upon its
genetic background. These findings provide key insights
into the challenge that drug resistance poses for the
control of infectious diseases like leishmaniasis.
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[34]. The resulting cDNA was 10 times diluted and used for
quantitative PCR of 11 genes as described elsewhere [34]. Briefly,
the mRNA levels of the 11 genes were determined at the 8
different time-points during promastigote growth in 1 quantitative
experiment. The analysis of 11 genes in 144 samples could be
performed as 1 integrated experiment by performing inter-plate
calibrations (based on 3 samples included in each quantitative
PCR-run) and centralised data-management with the qBase
software package [35].
Quantitative protein profiling by Western blot and
comparative analysis
Duplicate pellets of 16108 promastigotes were harvested for
each line at 4 different time-points during promastigote growth,
washed in PBS and lysed by repeated aspiration in ice-cold lysis
buffer (0.25 M sucrose, 0.25% triton X-100, 10 mM EDTA)
containing a protease inhibitor mix (10 mM E-64, 2 mM 1,10-
phenanthrolin, 4 mM pepstatin A, 1 mM phenylmethylsulfonyl-
fluoride). Cell debris was removed by centrifugation at 120006 g
for 10 min at 4uC. The soluble protein fraction was fractionated
on a 12% SDS-PAGE and electroblotted to nitrocellulose
membranes (Amersham Biosciences). Membranes were blocked
for 2 hrs at room temperature in TBS containing 5% milk and
0.2% Tween 20. Immuno-blotting of proteins of interest was done
overnight with the primary antibodies anti-TR (trypanothione
reductase) and anti-MST (mercaptopyruvate sulfurtransferase).
Protein loading per well was assessed with anti-OPB (oligopepti-
dase B) antibody which was shown to have a stable expression
Figure 1. Overview of Leishmania pathways involved in response to SSG. The defence against oxidative and nitrosative radicals imposed by
macrophages relies on antioxidants here represented in the thiol pool with 3 major thiols: (a) cysteine with 2 synthesis pathways in trypanosomatids
including transsulfuration pathway (as in vertebrates) via homocysteine with a key enzyme cystathione b-synthase (CBS) (#1), and de novo synthesis
from serine (as in some prokaryotes and eukaryotes) catalysed by cysteine synthase (CS) (#2); with sulfide possibly provided by mercaptopyruvate
sulfurtransferase (MST) (#3) [60,61]; (b) glutathione (GSH) synthesised by condensation of cysteine and glutamate with the key enzyme c-
glutamylcysteine synthase (GCS) (#4) [62]; and (c) trypanothione (T(SH)2) which is synthesised by condensation of glutathione and spermidine; with
ornithine decarboxylase (ODC) as key enzyme of spermidine synthesis (#5) [63]. Maintenance of redox balance is centred around the strong
reductant T(SH)2 and the flavo-enzyme trypanothione reductase (TR) which keeps the T(SH)2 pool reduced and the redox potential low (#6) [40,63–
65]; MST possibly also has an antioxidant role via thioredoxin (#7) [61]. The drug SbV can be taken up by the parasite via an unidentified transporter
(#8) [66] and the reduced form SbIII gains access via aquaglyceroporin (AQP1) (#9) [67]. The reduction of SbV to SbIII involves thiols and can be a
non-enzymatical spontaneous reduction [68–71], or enzymatically catalyzed by thiol dependent reductase 1 (TDR1) [72] or arsenate reductase 2
(ACR2) [73] (#10). The resulting SbIII can form conjugates with thiols and inhibit TR (#12), together leading to increase of redox potential [12–14,39].
The SbIII/thiol conjugates can be sequestered by ABC transporter multidrug resistance protein A (MRPA) or possibly pentamidine resistance protein 1
(PRP1) [74,75] into intracellular organelles (#13), or can be directly pumped out by an uncharacterised transporter (#14) [76] (boxed
names =proteins of which the corresponding genes were chosen for DNA sequencing and gene expression profiling in this study, unboxed
names =metabolites; used abbreviations: ROI = reactive oxygen intermediates, RNI = reactive nitrogen intermediates).
doi:10.1371/journal.pntd.0001514.g001
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throughout Leishmania promastigote growth [36]. The secondary
antibodies used were rabbit anti-IgG and antibodies were detected
using peroxidise-linked anti-rabbit IgG and ECL reagents (Pierce).
The Western blots were digitally analysed using the software
package Image J 1.386 (NIH, USA). The background of all blots
was subtracted automatically before measuring the intensity of
specific bands. Integrated densities for each band were determined
for each protein of interest and its corresponding loading control.
The ratio of the band intensity of the protein of interest versus the
band intensity of the corresponding loading control was used as
relative protein expression level and allowed comparison with
other samples. All duplicate samples for each of the 4 time-points
of 1 particular line were analysed in 1 blot.
Quantification thiol levels using HPLC and comparative
analysis
Thiol levels were quantified by HPLC as described previously
[37] with minor modifications. Briefly, triplicate cultures of
2.56107 promastigote were harvested at 4 different time-points
during promastigote growth and were prepared independently for
thiol quantification. Following cold washing steps to remove
extracellular medium, each pellet was resuspended in 40 mM
HEPPS in 2 mM EDTA, pH 8.0 containing 0.7 mM TCEP and
incubated for 45 min at room temperature during which cellular
thiols were reduced by the agent TCEP. The reduced thiols were
subsequently derivatised by adding 50 mL 2 mM monobromobi-
mane, a fluorescent thiol-specific reagent, and immediate heating
for 3 min at 70uC. After briefly cooling on ice and a
deproteinisation step, the resulting supernatant with the deriva-
tised thiols was kept for HPLC analysis. Separation and
quantification of the derivatised thiols was done by high pressure
liquid chromatography (HPLC, Dionex). The 3 thiols cysteine
(CSH), glutathione (GSH) and trypanothione (T(SH)2) could be
confidently identified in Leishmania extracts through comparison
with chromatograms of commercially available cysteine (Sigma),
glutathione (Sigma) and trypanothione (BACHEM). These
commercially available thiols were also used to prepare standard
solutions containing all 3 thiols in variable concentrations but with
a total thiol concentration comparable to the content of a
Table 1. Geographic, clinical and biological characteristics of L. donovani strains.
parasite isolate code
A.I. SSG
isolatea
derived
clones
A.I. SSG
clonea
origin
(district)
SSG treatment
outcome population DNAc RNAb proteinc thiolc
stress
testc
MHOM/NP/03/BPK206/0 1 clone 10 1 Sunsari definite cure A 3 3 3 3 3
clone 14 1 3 3 3
clone 20 1 3 3 3
MHOM/NP/02/BPK090/0 1 na na Sunsari definite cure A 3
MHOM/NP/02/BPK091/0 1 na na Sunsari definite cure A 3
MHOM/NP/03/BPK282/0 1 clone 4 1 Sunsari definite cure B 3 3 3 3 3
clone 9 1 3 3 3
MHOM/NP/03/BPK294/0 2 clone 1 2 Siraha definite cure B 3 3
MHOM/NP/02/BPK035/0 1 clone 1 1 Saptari definite cure B 3 3
MHOM/NP/02/BPK043/0 1 clone 2 1 Sunsari definite cure B 3 3
MHOM/NP/03/BPK181/0 1 na na Sunsari relapse B 3
MHOM/NP/03/BPK190/0 6+ clone 3 6+ Morang non-responder A 3 3 3 3 3
clone 11 6+ 3 3 3
clone 19 6+ 3 3
MHOM/NP/02/BPK025/0 6 na na Sunsari definite cure A 3
MHOM/NP/02/BPK087/0 6+ clone 11 5 Morang definite cure A 3 3 3
MHOM/NP/03/BPK279/0 6+ na na Morang definite cure A 3
MHOM/NP/03/BPK298/0 6+ clone 8 1 Sunsari definite cure A 3 3
MHOM/NP/03/BPK275/0 6+ clone 12 6+ Morang non-responder B 3 3 3
clone 15 6+ 3 3
clone 17 6+ 3 3
clone 18 6+ 3 3 3 3
MHOM/NP/02/BPK085/0 6+ clone 3 6+ Saptari definite cure B 3 3
clone 8 6+ 3 3
MHOM/NP/02/BPK164/1 6+ na na Dhanusa non-responder B 3
MHOM/NP/02/BPK177/0 6 na na Dhanusa relapse B 3
MHOM/NP/02/BPK178/0 6 clone 3 1 Sunsari definite cure B 3 3
MHOM/NP/03/BPK181/12 6 na na Sunsari relapse B 3
a= in vitro antimonial susceptibility as described in Rijal et al. [8], A.I. or activity index is defined as the ratio of the EC50 of a particular isolate or clone versus the EC50 of
reference isolate sensitive to SSG. The activity index is used to express the in vitro susceptibility of that tested isolate or clone, isolates or clones with an activity index
between 1 and 2 are considered as sensitive to antimonials (white background), while those showing an activity index between 3 and 6 are considered to be in vitro
resistant (grey background), b=experiment done with clinical isolates, c=experiment done with clones derived from clinical isolates.
doi:10.1371/journal.pntd.0001514.t001
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Leishmania lysate. The obtained thiol mixtures were used to
determine (i) the correlation between fluorescence peak area and
thiol concentration and (ii) the linear range of detection. A volume
of 25 mL of each prepared derivatised Leishmania extract was
injected on the column for thiol quantification. A mobile phase
consisting of 0.25% acetic acid (solvent A) and 100% acetonitrile
(solvent B) was applied to separate the different thiols. Gradient
elution started with 100% solvent A and 0% solvent B. After
40 min, solvent B was increased to 8% for 60 min, to 15% for the
subsequent 10 min, and finally to 50% for 1 min. The system
returned to the initial solvent composition with 0% solvent B for
the remaining 10 min of the run. Thiols were detected as they ran
off the column by a fluorescence spectrophotometer (excitation
365 nm, emission 480 nm).
In vitro promastigote susceptibility test for oxidative and
nitrosative stress and comparative analysis
Promastigote susceptibility for 3 different oxidative/nitrosative
stresses (Table 2) was assessed using Alamar blue (AB) assays as
described elsewhere [38], with minor modifications. Briefly, at 3
different time-points during promastigote growth, parasites were
plated in quadruplicate in 96-well plates at an initial density of
56105 parasites/ml for 48 hrs incubation experiments. Each
well with 100 ml parasite culture was topped with 100 ml drug
solution prepared in 6 different dilutions (Table 2). The following
drugs were used: Perdrogen hydrogen peroxide 30 WT %
(Sigma-Aldrich), S-Nitroso-N-acetylpenicillamine (SNAP, Bio-
mol International), and potassium antimonyl tartrate trihydrate
(SbIII, Sigma-Aldrich). Quadruplicate untreated controls and
blanks were included in each test plate. The culture plates were
sealed and incubated at 26uC. AB reagent (Invitrogen) was
added 24 hrs before the end of drug incubation to test cell
viability, and AB fluorescence was read at the end of the drug
incubation using 555 nm excitation wavelength and 585 nm
emission wavelength.
AB fluorescence data from treated and non-treated cultures was
used to calculate the IC50 by sigmoidal regression analysis (with
variable slope) using GraphPad Prism v.5.02.
Statistical analysis
The change of all measured variables (RNA/protein/thiol/
IC50) was evaluated (i) in relation to the SSG-phenotype and (ii)
Table 2. Conditions used for the oxidative/nitrosative stress phenotyping assays of L. (L) donovani clones.
Drug nature stress final drug concentration (range tested)
H202 direct oxidative 0–100–150–300–500–1000–1500 mM
SNAP (NO-donor) direct nitrosative 0–5–20–50–150–300–500 mM
SbIII indirect oxidative+nitrosative 0–2–7–20–70–200–700 mg/mL
doi:10.1371/journal.pntd.0001514.t002
Figure 2. Geographic distribution of studied L. (L.) donovani isolates with population and in vitro SSG susceptibility information.
doi:10.1371/journal.pntd.0001514.g002
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in relation to time during in vitro growth with a repeated
measures two-way ANOVA (ANOVA p-value indicated under
each heatmap) followed by Bonferroni post-tests (significance
indicated by an asterisk under each time point). Since
experiments were repeated at different time-points during
promastigote growth, the analysis was done with matching by
time-points. Statistical analysis was done with GraphPad Prism
v.5.02 from GraphPad Software, Inc. Heatmaps were plotted in
R (www.r-project.org) using the plotting tools of the packages
gplots and RColorbrewer.
Results
We selected 19 L. (L.) donovani clinical isolates with documented
differential in vivo and in vitro SSG-susceptibility [8]: 8 of those
isolates are in vitro sensitive to SSG (SSG-S) and 11 are in vitro
Figure 3. In vitro promastigote growth profiles of studied L. (L.) donovani isolates. The growth profiles of population A isolates (in black
dotted curves) and population B isolates (in full black curves) largely coincide and clearly indicate that all studied isolates had a similar in vitro
promastigote growth dynamic. The growth curve shown for each isolate represents the average growth assessed in 3 repeated experiments.
doi:10.1371/journal.pntd.0001514.g003
Table 3. Relative expression levels of 11 genes in the different biological groups of L. donovani isolates.
gene
ALL ISOLATES differences
between SSG-S and SSG-R
POPULATION A differences
between SSG-S and SSG-R
POPULATION B differences
between SSG-S and SSG-R
CBS yes (P =0.050) yes (P =0.035) no (P = 0.565)
GCS yes (P =0.034) no (P = 0.061) no (P = 0.432)
MST yes (P =0.037) no (P = 0.719) yes (P=0.001)
TR no (P = 0.086) no (P = 0.063) no (P = 0.742)
ACR2 no (P = 0.188) no (P = 0.354) no (P = 0.251)
AQP1 no (P = 0.095) no (P = 0.250) no (P = 0.671)
CS no (P = 0.815) no (P = 0.801) no (P = 0.923)
ODC no (P = 0.124) no (P = 0.487) no (P = 0.138)
TDR1 no (P = 0.633) no (P = 0.802) no (P = 0.829)
PRP1 no (P = 0.847) no (P = 0.619) no (P = 0.599)
MRPA no (P = 0.851) no (P = 0.873) no (P = 0.399)
Statistical analysis: P-values comparing the indicated groups of isolates were determined by repeated measures two-way ANOVA with matching by time-points. Data
were missing from time-point ‘day 7’ and needed to be excluded from statistical analysis. The complete dataset of average relative gene expression levels (6 SD)
measured during 8 consecutive days in vitro promastigote growth can be found in dataset S1.
doi:10.1371/journal.pntd.0001514.t003
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resistant to SSG (SSG-R). Within this particular collection of L.
(L.) donovani clinical isolates, kDNA fingerprinting showed there to
be 2 distinct genotypic populations (here designated as population
A and population B) differentiated by the highest minicircle
sequence dissimilarity [15]. Population A (eight isolates) which is
genetically very homogeneous and found in only 2 Eastern
Nepalese districts, Sunsari and Morang (Figure 2), is thought to
result from a recent clonal expansion [15]. In contrast, population
B (eleven isolates) is much more heterogeneous at kDNA level than
population A [15], and was found in the entire VL endemic region
of Nepal (Figure 2). The higher homogeneity of population A
(versus population B) was confirmed by whole genome sequencing
[16] and genome-wide SNP typing [17]. PCA analysis revealed
that population A clusters separately from population B (see fig. 1
in ref [16]) due to 35 homozygous SNPs - 19 coding, 11 non-
synonymous and 8 synonymous. Populations A and B should be
considered at present as model populations, as the parasite
isolation success rate is only around 60% we cannot yet exclude
the possibility that parasites with other genetic backgrounds occur
in the region. Table 1 gives an overview of the geographical,
clinical and biological characteristics of all parasite isolates (and
derived clones) included in this study.
We comparatively characterised in vitro promastigotes of these L.
(L.) donovani isolates (and derived clones) on the level of DNA
sequence, RNA expression, protein expression, thiol content and
oxidative/nitrosative stress phenotype. For the last 4 experiments,
we monitored and sampled the promastigote cultures during 8
days in vitro growth, a process which consists of a logarithmic phase
(day 1 to day 4) during which the parasites multiply, and a
stationary phase (day 5 to day 8) during which metacyclogenesis
(the development of the metacyclic promastigotes that are
infectious to humans) occurs. The strains studied here all had a
comparable in vitro growth dynamic (Figure 3). The purpose of this
time-course analysis was two-fold: (i) to detect quantitative
differences in parasite features at specific stages of growth, and
(ii) to detect differential regulation of parasite features over time.
Gene expression profiling of 11 targets
The gene expression levels of 11 target genes, selected on the
basis of their reported relevance in the parasite’s antioxidant
response to SSG or pathways known to be affected by SSG
(Figure 1), were assessed using quantitative PCR with 18 L. (L.)
donovani clinical isolates (Table 1). The detailed results of the gene
expression profiling experiments can be found in dataset S1.
Comparison of the expression profiles of all SSG-S and all SSG-
R isolates identified 3 genes (CBS, GCS and MST) with a
significantly different expression profile in the 2 groups of isolates
(Table 3). However, a more detailed analysis clarified that the
expression levels of these 3 genes do not represent molecular
markers of all SSG-R parasites, but rather characterise SSG-R
parasites in either population A or B (Table 3 and visualised in the
heatmaps of figure 4):
(i) In population A, the gene CBS has an overall significantly
higher expression in SSG-R isolates compared to SSG-S
isolates (P = 0.035). This difference gradually increases
during stationary phase to reach 1.3-fold by day 8
(Figure 4). In population B, on the other hand, CBS profiles
were similar for the 2 phenotypes (P = 0.565, Figure 4).
(ii) GCS expression also appears to differ between SSG-S and
SSG-R isolates of population A. Although we could not find
an overall significant difference in population A (P= 0.061),
the Bonferroni post-tests indicated that GCS expression
increases more steeply during stationary phase in SSG-R
compared to SSG-S isolates, with an average 1.5-fold
difference between the 2 phenotypes by day 8. In population
B, there was no difference between the SSG-S and SSG-R
isolates with all showing a similar increase in GCS expression
during stationary phase (P= 0.432).
(iii) MST expression was, in contrast, significantly different
between SSG-R and SSG-S isolates in population B
(P = 0.001) but not in population A (P = 0.719). In
population B, SSG-R isolates had a steeper increase during
stationary phase compared to SSG-S isolates, reaching an
average 1.8–1.9-fold difference at days 7 and 8 of culture.
Thus the SSG-R isolates are marked by an enhanced gene
expression during metacyclogenesis, however in each case in just
1 of the 2 populations studied. This heterogeneous profile for
expression of these genes in the SSG-R isolates contrasts with the
more homogenous profiles of the SSG-S isolates (Figure 4). The
hypothesis arising from these experiments, that SSG-R isolates in
the 2 populations have heterogeneous adaptations, instigated
further molecular and biochemical comparison of the isolates.
To avoid working with mixed parasite isolates for this
investigation, we produced clones (derived from a single parasite
picked from the isolate culture and grown as independent
culture) of selected clinical isolates which were confirmed to be
representative for population A and population B by whole
genome sequencing and SNP typing [16,17]. These clones
(characteristics shown in Table 1) were used for the remainder of
the study.
DNA sequencing of coding and neighbouring non-
coding regions of 11 genes of interest
Single nucleotide polymorphisms (SNPs) in the DNA sequence
of the 11 studied genes (Figure 1) could modify performance of the
encoded proteins (SNPs in coding regions) or could underlie the
observed changes in gene expression (SNPs in non-coding regions),
although such SNPs had not been reported previously in the
context of antimonial resistance in Leishmania. In our study, the
coding DNA sequence of the 11 genes of interest was determined
by Illumina sequencing for 11 different parasite clones (5 SSG-S
and 6 SSG-R, Table 1). All coding sequences were found to be
Figure 4. Heatmap of CBS, GCS and MST gene expression levels in 18 L. (L.) donovani isolates. The color key shown for each gene reveals
the color-code used to visualise the relative gene expression values which were determined by Q-PCR, light red colors correspond to low relative
gene expression levels while dark red colors correspond to high relative gene expression levels. An identical color key was used to present all results
of 1 particular gene and allows comparison of gene expression levels between the 2 populations (population A in heatmap on the left, population B
in heatmap on the right). The sampled isolates are presented along the Y-axis, their SSG-susceptibility status is indicated by the white (SSG-S)/grey
(SSG-R) sidebars. Relative gene expression levels determined at 4 consecutive days during stationary phase of promastigote growth are visualised
(data from logarithmic growth phase are not shown here); the included time-points are indicated on the X-axis. The P-value shown for each
population reflects the overall similarity between the gene expression-profiles of SSG-S and SSG-R isolates within that population (repeated measures
two-way ANOVA), and the asterisks further mark the specific time-points where gene expression levels were found to be significant different
according to Bonferroni post-tests (* = P,0.05; ** = P,0.01, *** = P,0.001, **** = P,0.0001; {= time-point excluded from statistical analysis due to
missing values). The relative gene expression levels 6 SD determined at all 8 time-points (logarithmic and stationary phase) of promastigote growth
are given in dataset S1.
doi:10.1371/journal.pntd.0001514.g004
Heterogeneity of Drug Resistant Leishmania
www.plosntds.org 8 February 2012 | Volume 6 | Issue 2 | e1514
100% identical. Further screening of the neighbouring non-coding
upstream and downstream sequences of all genes revealed that the
upstream regions (500 bp) of the 11 genes were also completely
conserved among the 11 clones. Some SNPs were found in the
downstream regions (500 bp) of the genes coding for TR, MST
and ACR2, but the SNP pattern did not correlate with either the
Figure 5. Heatmap of MST and TR protein expression levels of 12 L. (L.) donovani clones. The Western blots were digitally analysed by
integrating the density of each protein band and its corresponding loading control (see materials and methods). The ratio of the band intensity of the
protein of interest versus the band intensity of the corresponding loading control was defined as the relative protein expression level. The color key
shown for each protein reveals the color-code used to visualise the relative protein expression level, light green colors correspond to low relative
protein expression levels while dark green colors correspond to high relative protein expression levels. An identical color key was used for the 2
heatmaps of 1 particular protein and allows comparison of protein expression levels between the 2 populations (population A in heatmap on the left,
population B in heatmap on the right). The sampled clones are presented along the Y-axis, their SSG-susceptibility status is indicated by the white
(SSG-S)/grey (SSG-R) sidebars. Average protein expression levels from duplicate cultures were assessed at 4 different days during promastigote
growth; the included time-points are indicated on the X-axis. The P-value shown for each population reflects the overall similarity between the
protein expression-profiles of SSG-S and SSG-R clones within that population (repeated measures two-way ANOVA), and the asterisks further mark
the specific time-points where protein expression levels were found to be significant different according to Bonferroni post-tests (* = P,0.05;
** = P,0.01, *** = P,0.001, **** = P,0.0001). The relative protein expression levels 6 SEM determined at the 4 time-points of promastigote growth
are given in dataset S3.
doi:10.1371/journal.pntd.0001514.g005
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Figure 6. Heatmap of thiol levels of 12 L. (L.) donovani clones. The color key shown for each thiol reveals the color-code used to visualise the
thiol quantities expressed in nmol/108 parasites, light blue values correspond to low concentrations while purple values correspond to high
concentrations. An identical color key was used for the 2 heatmaps per thiol and allows comparison of thiol quantities between the 2 populations
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genotypic diversity (populations A and B) or the SSG-susceptibil-
ity. The sequencing data are detailed in dataset S2.
Protein expression profiling
Our protein analysis experiments focussed on MST and TR.
The gene encoding MST was the one showing the most significant
differential gene expression-profile between SSG-S isolates and
SSG-R isolates (in pop. B) of all the genes analysed (Table 3). TR,
on the other hand, did not have significantly different gene
expression-profiles in the SSG-S and SSG-R isolates tested here,
but has been implicated as a target of SbIII, the active form of
SSG (Figure 1) [12,14,39]. We determined by Western blot
analysis the relative protein levels within the measurable range at 4
different days during the 8-day promastigote growth for 6 clones of
each population (Table 1).
The digitally integrated protein expression levels of TR and
MST are visualised in the heatmaps of figure 5; the full dataset is
given in dataset S3. MST expression-profiles were overall similar
within population A (P= 0.450) and within population B
(P = 0.469). The protein profiles of TR are also comparable
amongst the clones of population A (P= 0.964), but in population
B the SSG-R clones were found to have an average 3.9-fold lower
protein level compared to the SSG-S clones (P = 0.018, Figure 5).
Bonferroni post-tests indicated that this difference was statistical
significant at 3 out of 4 time-points tested.
Thiol quantity profiling
Thiols are the central metabolites of Leishmania’s redox
metabolism [40], and in this study were quantified at 4 different
days during the 8-day promastigote growth for 6 clones of each
population (Table 1). The resulting thiol quantities are in the same
range as reported by other L. (L.) donovani studies [41]. The
complete thiol quantification data are given in dataset S4.
The thiol levels in the 2 populations are visualised in the
heatmaps of figure 6. The trypanothione and cysteine profiles are
generally comparable for all tested clones. We also did not find a
correlation between glutathione levels and SSG-susceptibility of
the tested clones. However there was a significant overall
difference in glutathione levels between population A and B, with
the clones of population B having an average 1.5-fold higher
glutathione level compared to those of population A (P= 0.0004).
Although the levels detected were significantly different, it is not
possible with the current knowledge to know whether or not such a
small variation is of any biological significance. Interestingly,
differences were found between the cysteine and glutathione levels
in log and stationary phase promastigotes, however as this was not
central to this study it was not investigated further
In vitro oxidative/nitrosative stress phenotyping
In vitro oxidative and nitrosative stress exposure of promastigotes
was chosen as a phenotypic approach to verify if the molecular
modifications leading to L. (L.) donovani SSG-resistance confer a
modified tolerance to oxidative/nitrosative stress, which has been
hypothesised from many other studies [21,23,26–29]. We exposed
6 clones of each population (Table 1) to 3 different oxidative/
nitrosative stresses: (i) hydrogen peroxide (H202), a powerful
oxidising agent; (ii) S-nitroso-N-acetylpenicillamine (SNAP), an
NO donor imposing a nitrosative stress; and (iii) SbIII, a metalloid
compound closely related to SSG which imposes an indirect
oxidative/nitrosative stress by binding thiols and inhibiting the
enzyme TR [12–14]. The stress susceptibility of the clones was
determined on 3 consecutive days (days 5 to 7) during the
stationary phase of the 8-day promastigote cultures. Table 2
summarises the conditions of the performed in vitro susceptibility
tests.
The results of the stress susceptibility tests are shown in
heatmaps in figure 7 which visually highlight one common finding
for all 3 stresses: all clones of population A have a comparable
stress-susceptibility, while in population B the SSG-R clones have
a significantly different stress-susceptibility profile compared with
the SSG-S clones. The susceptibility differences between SSG-S
and SSG-R in population B, however, are not of the same nature
and magnitude for the 3 compounds used. The difference is most
pronounced for H202, with the tested SSG-R clones having a
stable 1.6-fold lower (on average) IC50 compared with the tested
SSG-S clones (P = 0.0003). The difference in SNAP susceptibility
between the 2 phenotypes (P = 0.0004) varied during growth. The
SNAP-tolerance of the SSG-R clones increased more steeply
during stationary phase compared with the SSG-S clones.
Consequently the difference between the 2 phenotypes was less
significant as stationary phase progressed, and was almost non-
existent by the end of stationary phase (day 7). The SbIII-
susceptibility difference between the 2 phenotypes (P = 0.029) also
changed during stationary phase. At the beginning of stationary
phase, the SSG-R clones had a 2.3-fold lower SbIII tolerance
compared with the SSG-S clones. However, the SbIII IC50 values
of the SSG-S clones decreased drastically as stationary phase
progressed, while those of the SSG-R clones remained approxi-
mately stable. The result is that the SSG-R clones had an average
41-fold higher SbIII tolerance compared with SSG-S clones by
day 7. This SbIII tolerance difference at the end of stationary
phase (when more infectious parasite forms are present) is
consistent with the difference in SSG susceptibility of the
subsequent intracellular amastigote life-stage. It is also of note
that the steep drop in SbIII tolerance observed during stationary
phase of the SSG-S clones in population B was not seen in any of
the clones of population A, thus represents a significant phenotypic
difference between the 2 populations (P = 0.041).
Discussion
The primary aim of our study was to assess and attempt to
correlate the molecular and phenotypic heterogeneity in parasite
populations under drug treatment pressure. For this purpose we
characterised a sample of L. (L.) donovani isolates that belong to 2
genetically distinct populations circulating in the VL endemic
region of Nepal. In order to guarantee (i) reliable comparison of
data collected in for numerous parasite lines and (ii) meaningful
integration of data collected with various experimental approach-
es, it was of critical importance to use an experimental design
based on highly standardised protocols. It is extremely difficult to
achieve such standards when studying intracellular amastigotes,
the clinical relevant form of the parasite, which need to be
(population A in heatmap on the left, population B in heatmap on the right). In addition, the actual thiol quantities are shown as labels on the
heatmap. The tested clones are presented along the Y-axis, their SSG-susceptibility status is indicated by the white (SSG-S)/grey (SSG-R) sidebars.
Average thiol levels from triplicate cultures were determined at 4 different days of promastigote growth; the included time-points are indicated on
the X-axis. The P-value shown for each population reflects the overall similarity between the thiol levels of SSG-S and SSG-R clones within that
population (repeated measures two-way ANOVA), {= time-point excluded from statistical analysis due to missing values. The thiol quantities 6 SEM
determined at the 4 time-points of promastigote growth are given in dataset S4.
doi:10.1371/journal.pntd.0001514.g006
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Figure 7. Heatmap of in vitro oxidative and nitrosative stress susceptibility of 12 L. (L.) donovani clones. The color key shown for each
stress test reveals the color-code used to visualise the determined IC50-values, light yellow colors correspond to low IC50-values and dark orange
colors correspond to high IC50-values. An identical color key was used for the 2 heatmaps per stress-test and allows comparison of IC50-values
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generated by in vitro macrophage infections [34]. Axenic
amastigote culture techniques have been developed to overcome
in part this limitation, but can only be used with parasites that are
well-adapted to in vitro culture which is normally not the case for
clinical isolates [42,43]. Hence we chose to work with promasti-
gotes, the form of the parasite that resides in the insect vector,
which can be relatively easily and consistently cultured in vitro. We
also chose to perform time-course analyses based on samples taken
at different days during promastigote growth, an approach which
we have applied previously to increase sensitivity and robustness in
experimental studies of Leishmania [34]. Recent studies showed a
dramatic down-regulation of gene expression from stationary
phase promastigote to amastigotes, highlighting the functional
importance of the former stage and supporting the hypothesis of a
pre-adaption for intracellular life as an amastigote [44,45], we
cannot assume that the SSG-R features identified here in
stationary phase promastigotes are also present in the correspond-
ing amastigote stage. This limitation curtails confirmation of the
role of the identified putative SSG-R markers in the resistance
mechanisms active in amastigotes, nevertheless, as discussed below
in detail, the identified promastigote characteristics provide
significant new insights regarding the nature of the SSG-resistant
phenotype in natural Leishmania populations.
Molecular features of SSG-R population A and SSG-R
population B reveal heterogeneity among SSG-R L. (L.)
donovani
We identified in this study a number of molecular and
phenotypic features that correlate with the SSG-R phenotype.
However, none of those markers were found to be common for all
SSG-R lines included in this study (overview in Table 4) but were
specific for either population A or B.
The SSG-R isolates of population A were characterised by
elevated mRNA abundance of CBS and GCS in comparison to
the SSG-S isolates of population A (Table 3 and Figure 4), but the
underlying genetic polymorphism of these mRNA differences
could not be identified as SNPs in the neighbouring untranslated
regions (UTRs) could not be correlated to the differential gene
expression profiles between SSG-S and SSG-R strains. This does
not, however, exclude the possibility for changes in trans-
regulatory elements. CBS and GCS encode key enzymes for the
biosynthesis of the thiols cysteine and glutathione, respectively,
which confer protection against oxidant stresses (Figure 1)
[27,40,46,47]. However in our sample, we did not detect a
concomitant increase of thiol levels (Figure 6), nor an increased
oxidative/nitrosative stress tolerance of the SSG-R clones
compared to the SSG-S clones of population A (Figure 7). This
is in contrast to what was reported for Indian L. (L.) donovani,
where increased GCS gene expression linked to increased thiol
levels in the promastigote stage have been frequently described in
SSG-R clinical isolates [21,23,27,29]. At this point it is unclear
what other role(s) increased CBS and GCS mRNA abundance
could play in SSG-resistance of population A.
In population B, the SSG-R isolates were found to have a
significantly up-regulated gene expression of the sulfurtransferase
MST (Table 3, Figure 4). However, we could not identify the
underlying genetic polymorphism (mutations in the UTR’s did not
correlate with SSG-susceptibility) and protein profiling demon-
strated that this mRNA difference is not translated to the level of
protein (Figure 5). Hence, like the enhanced CBS/GCS gene
expression in population A, it is not clear what role up-regulated
MST gene expression plays in the SSG-resistance mechanism in
population B. At the protein level, the enzyme TR was found to be
present in significant lower quantities in SSG-R clones compared
to SSG-S clones (Figure 5). This differential protein profile
presumably results from distinct post-transcriptional regulation in
the 2 phenotypes since upstream TR mRNA levels of all
population B isolates were similar (Table 3). A decrease of the
enzyme TR signifies a decrease of an important antimonial target
in the parasite, and could thus represent the basis of the SSG-
resistance mechanism of population B. It is nevertheless surprising
to find decreased levels of TR as part of a successful Leishmania
adaptation since the enzyme TR has a central role in the
protection against oxidants in the host [48–50] (Figure 1). One
would expect that the observed four-fold decrease in TR protein
would interfere with the parasite’s capacity to manage oxidative/
nitrosative stress. The stress susceptibility tests of this study indeed
revealed that in population B, the tested SSG-R clones have a
significant different oxidative/nitrosative stress tolerance com-
Table 4. Exploration of parasite pathways known to be affected by antimonial drugs at five experimental levels.
population A only SSG-R vs SSG-S population B only SSG-R vs SSG-S population A vs population B
DNA sequence no differences no differences no differences
gene expression higher levels of CBS and GCS in SSG-R higher levels of MST in SSG-R no differences
protein expression no differences lower levels of TR in SSG-R no differences
thiols no differences no differences higher glutathione levels in population B
oxidative/nitrosative stress
tolerance
no differences lower tolerance for H202, SNAP and
SbIII in SSG-R
differential regulation of SbIII tolerance
during growth
Summary of differences between (i) SSG-S parasites versus SSG-R parasites within a specific population, and (ii) all studied parasites of population A compared with
population B.
doi:10.1371/journal.pntd.0001514.t004
between the 2 populations (population A in heatmap on the left, population B in heatmap on the right). In addition, the actual IC50-values are shown
as labels on the heatmap. The tested clones are presented along the Y-axis, their SSG-susceptibility status is indicated by the white (SSG-S)/grey (SSG-
R) sidebars. Stress susceptibility was assessed on 3 consecutive days during stationary phase of promastigote growth; the included time-points are
indicated on the X-axis. The P-value shown for each population reflects the overall similarity between the susceptibility-profiles of SSG-S and SSG-R
clones within that population (repeated measures two-way ANOVA), and the asterisks further mark the specific time-points where stress-
susceptibility was found to be significant different according to Bonferroni post-tests (* = P,0.05; ** = P,0.01, *** = P,0.001, **** = P,0.0001;
{= time-point excluded from statistical analysis due to missing values). All IC50-values 695% CI are given in dataset S5.
doi:10.1371/journal.pntd.0001514.g007
Heterogeneity of Drug Resistant Leishmania
www.plosntds.org 13 February 2012 | Volume 6 | Issue 2 | e1514
pared to the SSG-S clones (Figure 7). The reduced TR levels and
associated modified oxidative/nitrosative stress management are a
prominent tandem hallmark of antimonial-resistance in population
B, but not in population A where TR protein levels and likewise
responses to oxidant stresses were generally conserved.
Genetic parasite diversity is an underlying cause for
molecular heterogeneity in SSG-R parasites
The distinct profiles of SSG-R parasites in the 2 studied
populations provide strong evidence that the evolved molecular
mechanisms leading to the SSG-resistant phenotype differ between
the 2 populations (Table 4). The key question that arises is which
factors drive this divergent adaptation to antimonial treatment.
Several studies hypothesised that stress factors inherent to the
natural environment of Leishmania (e.g. oxidative stress from the
host cell, environmental arsenic contamination) can influence the
mechanisms of adaptation to antimonial pressure [6,51,52].
Differential exposure to such environmental stress factors
theoretically could result in differential molecular changes in
SSG-R parasites. However, it seems unlikely that environmental
differences have been the driving force in shaping the SSG-R
heterogeneity in the studied parasite sample, since the 2 studied
populations originate from the same endemic region and are likely
to have been exposed to similar environmental stresses.
Based on the findings of this study, we hypothesize that
differences in genetic background were a major driving force in
the development of heterogeneous SSG-R phenotypes. The
parasite’s genetic background determines the parasite’s intrinsic
capacity to cope with antimonial stress, and this intrinsic capacity
is likely to vary to some extent between distinct genetic
populations. For instance, the distinct genetic background of the
2 populations studied here is manifested as population differences
in antimonial detoxifying metabolites (glutathione) and antimonial
stress response (SbIII IC50, Table 4). We postulate that the success
of emerging mutations to confer antimonial-resistance to a
particular parasite population can depend on the specific
antimonial metabolising character of that population. For
instance, a particular mutation might be successful in one
population and unsuccessful in another population because the
intrinsic antimonial metabolism of the 2 populations is differently
affected by that same mutation. Our results imply that the
mutation(s) which underlie the tandem TR/oxidant stress-feature
of SSG-R in population B have a beneficial effect in combination
with the population B background. As this TR-related mutation
has not surfaced in population A, it appears that the same
beneficial effect is not attained (or, at least, not attained as readily)
in combination with the population A background. Drug-
resistance studies on other pathogens including Plasmodium
falciparum and Mycobacterium tuberculosis also reported that the effect
of specific drug-resistance mutations can depend on the strain
genetic background [53,54]. It has been proposed that this relation
between genetic background and drug-resistance mutations
reflects a form of epistasis. Epistasis occurs when the phenotypic
effect of a mutation changes depending on the presence or absence
of other mutations in the same genome [55]. In the context of
drug-resistance, epistasis is thought to become manifest when a
particular drug-resistance mutation has a different fitness effect
depending on the strain’s genetic background [56,57].
A picture emerges in which each genetically distinct population
can (and perhaps is likely to) develop a SSG-resistant phenotype
with a different molecular basis. This completely transforms
current perceptions of Leishmania drug resistance, in which it is
frequently presumed that there is a single dominant molecular
feature which underlies the SSG-R phenotype encountered in the
field. The multitude of clinical L.(L.) donovani resistance markers
already reported in the literature [20–23,26–29] appeared
incoherent, and sometimes incongruent (e.g. SSG-R markers of
Indian vs Nepalese strains), but our data suggest that those findings
should be re-interpreted taking into account the genetic back-
ground of the various studied parasite samples. Further studies are
needed to investigate in what way the various identified SSG-R
molecular features interact with the genetic background of the
respective natural populations to convey the antimonial resistant
phenotype. Additional isolates with a different genetic background
from those of populations A and B (if any should be found) will
also be considered in future studies. Epidemiological surveillance
of Leishmania drug resistance is currently impeded by the lack of
molecular-based tools to monitor the emergence and spreading of
antimonial resistant parasites [2,58,59]. It now seems that the
putative high degree of molecular heterogeneity in SSG-resistant
parasites needs to be included as a key factor when designing
molecular tools to monitor SSG-resistance.
Supporting Information
Dataset S1 Relative gene expression levels of 11 target
genes in 18 L. (L.) donovani isolates with variable SSG
susceptibility during 8 consecutive days of in vitro
promastigote growth. The given relative gene expression
levels (6 SD) are the average of 3 repeated measurements in 1
experiment using the same RNA sample. (NA= result not
available).
(DOC)
Dataset S2 DNA sequence of 11 target genes in 11 L. (L.)
donovani clones with variable in vitro SSG susceptibil-
ity. The coding DNA sequences (+500 basepairs upstream and
downstream) of 11 proteins reported to be involved in SSG/SbV/
SbIII metabolism were determined by Illumina sequencing in 11
L. (L.) donovani clones with differential in vitro SSG susceptibility.
(DOC)
Dataset S3 Relative levels of the proteins trypanothione
reductase (TR) and mercaptopyruvate sulfurtransferase
of 12 L. (L.) donovani clones with variable SSG
susceptibility during 8 consecutive days of in vitro
promastigote growth. The given relative protein expression
levels (6 SEM) are the average of 2 independent samples prepared
from parallel cultures which were analysed on the same Western
Blot, the listed values correspond to the normalised digitally
integrated intensities of the protein bands. (NA= result not
available).
(DOC)
Dataset S4 Thiol levels of 12 L. (L.) donovani clones
with variable SSG susceptibility during 8 consecutive
days of in vitro promastigote growth. The thiol quantities
(6 SEM) are the average of 3 independent samples prepared from
parallel cultures which were analysed in 1 HPLC experiment, the
listed values are expressed in nmol/108 parasites. (NA= result not
available).
(DOC)
Dataset S5 In vitro susceptibility to H202, SNAP and
SbIII of 12 L. (L.) donovani clones with variable SSG
susceptibility during 8 consecutive days of in vitro
promastigote growth. The given IC50 values [695 CI] were
determined by sigmoidal regression analysis based on the %
parasite viability following 48 hrs exposure to 6 different
concentrations of the tested compound. (NA= result not available).
(DOC)
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